Table 2.
Baseline characteristics of the ankylosing spondylitis patients treated with infliximab according to the response BASDAI50 after 6 months of infliximab
| Yes (n = 77)a |
No (n = 62)a |
P value | |
|---|---|---|---|
| Age (years), median (IQR) | 39.4 (32.0 -50.0) | 44.8 (38.2-53.0) | 0.0469 |
| Gender (% males) | 72.7 | 51.6 | 0.0102 |
| Disease duration (years), median (IQR) | 8.0 (4.0-14.0) | 6.0 (3.0-12.0) | 0.1966 |
| BMI (kg/m2) | 24.4 (21.9-26.8) | 28.7 (25.6-31.6) | < 0.0001 |
| HLAB27 (% of patients) | 73.3 | 56.9 | 0.0470 |
| Δweight (kg), median (IQR) | -1.0 (-2.0-2.0) | 0.0 (-2.0-3.0) | 0.4948 |
| Baseline CRP (mg/dl), median (IQR) | 14.0 (5.0-26.0) | 6.6 (3.0-13.0) | 0.0039 |
aTwo patients withdrew from IFX therapy (lack of response and serious adverse event) and BASDAI50 lacking data for 14 AS patients
BASDAI50, 50% improvement in the Bath Ankylosing Spondylitis Disease Activity Index; BMI, body mass index; CRP, C-reactive protein; IQR, interquartile range.